Logo image of MTD

METTLER-TOLEDO INTERNATIONAL (MTD) Stock Fundamental Analysis

USA - NYSE:MTD - US5926881054 - Common Stock

1287.1 USD
+13.14 (+1.03%)
Last: 9/18/2025, 7:00:00 PM
1287.1 USD
0 (0%)
After Hours: 9/18/2025, 7:00:00 PM
Fundamental Rating

5

Overall MTD gets a fundamental rating of 5 out of 10. We evaluated MTD against 55 industry peers in the Life Sciences Tools & Services industry. While MTD has a great profitability rating, there are some minor concerns on its financial health. MTD has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

MTD had positive earnings in the past year.
MTD had a positive operating cash flow in the past year.
MTD had positive earnings in each of the past 5 years.
Each year in the past 5 years MTD had a positive operating cash flow.
MTD Yearly Net Income VS EBIT VS OCF VS FCFMTD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

Looking at the Return On Assets, with a value of 24.40%, MTD belongs to the top of the industry, outperforming 98.18% of the companies in the same industry.
MTD has a better Return On Invested Capital (39.61%) than 96.36% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MTD is significantly above the industry average of 15.96%.
Industry RankSector Rank
ROA 24.4%
ROE N/A
ROIC 39.61%
ROA(3y)25.04%
ROA(5y)23.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)41.86%
ROIC(5y)39.3%
MTD Yearly ROA, ROE, ROICMTD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

MTD has a better Profit Margin (21.46%) than 94.55% of its industry peers.
In the last couple of years the Profit Margin of MTD has grown nicely.
The Operating Margin of MTD (28.61%) is better than 100.00% of its industry peers.
MTD's Operating Margin has improved in the last couple of years.
The Gross Margin of MTD (59.94%) is better than 78.18% of its industry peers.
In the last couple of years the Gross Margin of MTD has remained more or less at the same level.
Industry RankSector Rank
OM 28.61%
PM (TTM) 21.46%
GM 59.94%
OM growth 3Y2.77%
OM growth 5Y3.56%
PM growth 3Y2.52%
PM growth 5Y3.63%
GM growth 3Y0.93%
GM growth 5Y0.74%
MTD Yearly Profit, Operating, Gross MarginsMTD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MTD is creating value.
The number of shares outstanding for MTD has been reduced compared to 1 year ago.
Compared to 5 years ago, MTD has less shares outstanding
MTD has a worse debt/assets ratio than last year.
MTD Yearly Shares OutstandingMTD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
MTD Yearly Total Debt VS Total AssetsMTD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 10.16 indicates that MTD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.16, MTD belongs to the top of the industry, outperforming 94.55% of the companies in the same industry.
MTD has a debt to FCF ratio of 2.58. This is a good value and a sign of high solvency as MTD would need 2.58 years to pay back of all of its debts.
MTD's Debt to FCF ratio of 2.58 is amongst the best of the industry. MTD outperforms 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.58
Altman-Z 10.16
ROIC/WACC3.89
WACC10.18%
MTD Yearly LT Debt VS Equity VS FCFMTD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 1.12 indicates that MTD should not have too much problems paying its short term obligations.
MTD's Current ratio of 1.12 is on the low side compared to the rest of the industry. MTD is outperformed by 85.45% of its industry peers.
MTD has a Quick Ratio of 1.12. This is a bad value and indicates that MTD is not financially healthy enough and could expect problems in meeting its short term obligations.
MTD has a Quick ratio of 0.77. This is amonst the worse of the industry: MTD underperforms 89.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.77
MTD Yearly Current Assets VS Current LiabilitesMTD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

4

3. Growth

3.1 Past

MTD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.37%, which is quite good.
The Earnings Per Share has been growing by 12.53% on average over the past years. This is quite good.
MTD shows a small growth in Revenue. In the last year, the Revenue has grown by 3.10%.
The Revenue has been growing slightly by 5.18% on average over the past years.
EPS 1Y (TTM)8.37%
EPS 3Y6.67%
EPS 5Y12.53%
EPS Q2Q%4.56%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y1.37%
Revenue growth 5Y5.18%
Sales Q2Q%3.85%

3.2 Future

The Earnings Per Share is expected to grow by 9.06% on average over the next years. This is quite good.
Based on estimates for the next years, MTD will show a small growth in Revenue. The Revenue will grow by 4.03% on average per year.
EPS Next Y2.96%
EPS Next 2Y6.58%
EPS Next 3Y8.13%
EPS Next 5Y9.06%
Revenue Next Year3.3%
Revenue Next 2Y3.85%
Revenue Next 3Y4.33%
Revenue Next 5Y4.03%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MTD Yearly Revenue VS EstimatesMTD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
MTD Yearly EPS VS EstimatesMTD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20 40 60

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 31.47, the valuation of MTD can be described as expensive.
Based on the Price/Earnings ratio, MTD is valued a bit cheaper than 65.45% of the companies in the same industry.
MTD's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.41.
MTD is valuated quite expensively with a Price/Forward Earnings ratio of 27.53.
MTD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MTD is cheaper than 67.27% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, MTD is valued a bit more expensive.
Industry RankSector Rank
PE 31.47
Fwd PE 27.53
MTD Price Earnings VS Forward Price EarningsMTD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MTD indicates a somewhat cheap valuation: MTD is cheaper than 70.91% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, MTD is valued a bit cheaper than 67.27% of the companies in the same industry.
Industry RankSector Rank
P/FCF 31.27
EV/EBITDA 23.09
MTD Per share dataMTD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100 150

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MTD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)10.64
PEG (5Y)2.51
EPS Next 2Y6.58%
EPS Next 3Y8.13%

0

5. Dividend

5.1 Amount

MTD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

METTLER-TOLEDO INTERNATIONAL

NYSE:MTD (9/18/2025, 7:00:00 PM)

After market: 1287.1 0 (0%)

1287.1

+13.14 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-31 2025-07-31/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners102.05%
Inst Owner Change-1%
Ins Owners0.42%
Ins Owner Change2.98%
Market Cap26.51B
Analysts71.58
Price Target1330.37 (3.36%)
Short Float %3.31%
Short Ratio4.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.38%
Min EPS beat(2)2.78%
Max EPS beat(2)3.98%
EPS beat(4)4
Avg EPS beat(4)3.18%
Min EPS beat(4)1.02%
Max EPS beat(4)4.94%
EPS beat(8)6
Avg EPS beat(8)3.16%
EPS beat(12)10
Avg EPS beat(12)2.65%
EPS beat(16)14
Avg EPS beat(16)3.36%
Revenue beat(2)1
Avg Revenue beat(2)0.73%
Min Revenue beat(2)-0.18%
Max Revenue beat(2)1.63%
Revenue beat(4)3
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-0.18%
Max Revenue beat(4)2.56%
Revenue beat(8)5
Avg Revenue beat(8)0.5%
Revenue beat(12)8
Avg Revenue beat(12)0.25%
Revenue beat(16)12
Avg Revenue beat(16)0.61%
PT rev (1m)1.41%
PT rev (3m)3.56%
EPS NQ rev (1m)0.84%
EPS NQ rev (3m)1.82%
EPS NY rev (1m)0.93%
EPS NY rev (3m)1.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.26%
Revenue NY rev (1m)0.98%
Revenue NY rev (3m)1.03%
Valuation
Industry RankSector Rank
PE 31.47
Fwd PE 27.53
P/S 6.86
P/FCF 31.27
P/OCF 27.86
P/B N/A
P/tB N/A
EV/EBITDA 23.09
EPS(TTM)40.9
EY3.18%
EPS(NY)46.75
Fwd EY3.63%
FCF(TTM)41.16
FCFY3.2%
OCF(TTM)46.2
OCFY3.59%
SpS187.7
BVpS-12.56
TBVpS-58.08
PEG (NY)10.64
PEG (5Y)2.51
Profitability
Industry RankSector Rank
ROA 24.4%
ROE N/A
ROCE 48.24%
ROIC 39.61%
ROICexc 40.71%
ROICexgc 70.2%
OM 28.61%
PM (TTM) 21.46%
GM 59.94%
FCFM 21.93%
ROA(3y)25.04%
ROA(5y)23.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)41.86%
ROIC(5y)39.3%
ROICexc(3y)43.32%
ROICexc(5y)40.86%
ROICexgc(3y)78.59%
ROICexgc(5y)73.33%
ROCE(3y)50.98%
ROCE(5y)47.86%
ROICexcg growth 3Y5.41%
ROICexcg growth 5Y8.89%
ROICexc growth 3Y5.36%
ROICexc growth 5Y6.84%
OM growth 3Y2.77%
OM growth 5Y3.56%
PM growth 3Y2.52%
PM growth 5Y3.63%
GM growth 3Y0.93%
GM growth 5Y0.74%
F-Score7
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.58
Debt/EBITDA 1.73
Cap/Depr 85.07%
Cap/Sales 2.69%
Interest Coverage 250
Cash Conversion 77.47%
Profit Quality 102.18%
Current Ratio 1.12
Quick Ratio 0.77
Altman-Z 10.16
F-Score7
WACC10.18%
ROIC/WACC3.89
Cap/Depr(3y)92.83%
Cap/Depr(5y)94.35%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.89%
Profit Quality(3y)97.94%
Profit Quality(5y)100.58%
High Growth Momentum
Growth
EPS 1Y (TTM)8.37%
EPS 3Y6.67%
EPS 5Y12.53%
EPS Q2Q%4.56%
EPS Next Y2.96%
EPS Next 2Y6.58%
EPS Next 3Y8.13%
EPS Next 5Y9.06%
Revenue 1Y (TTM)3.1%
Revenue growth 3Y1.37%
Revenue growth 5Y5.18%
Sales Q2Q%3.85%
Revenue Next Year3.3%
Revenue Next 2Y3.85%
Revenue Next 3Y4.33%
Revenue Next 5Y4.03%
EBIT growth 1Y4.27%
EBIT growth 3Y4.18%
EBIT growth 5Y8.92%
EBIT Next Year5.85%
EBIT Next 3Y6.25%
EBIT Next 5Y6.82%
FCF growth 1Y-1.24%
FCF growth 3Y2.57%
FCF growth 5Y11.3%
OCF growth 1Y-1.81%
OCF growth 3Y2.14%
OCF growth 5Y9.92%